Oppenheimer Asset Management Inc. Has $4.32 Million Stock Position in Genmab A/S (NASDAQ:GMAB)

Oppenheimer Asset Management Inc. reduced its stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 10.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 207,107 shares of the company's stock after selling 25,136 shares during the quarter. Oppenheimer Asset Management Inc.'s holdings in Genmab A/S were worth $4,322,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Two Sigma Advisers LP grew its position in Genmab A/S by 84.1% during the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company's stock worth $14,996,000 after purchasing an additional 280,900 shares during the last quarter. ABC Arbitrage SA purchased a new position in Genmab A/S during the 4th quarter worth $3,692,000. Y Intercept Hong Kong Ltd grew its position in Genmab A/S by 371.0% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 73,696 shares of the company's stock worth $1,538,000 after purchasing an additional 58,048 shares during the last quarter. Natixis Advisors LLC grew its position in Genmab A/S by 29.8% during the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company's stock worth $5,036,000 after purchasing an additional 47,437 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Genmab A/S by 229.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company's stock worth $1,033,000 after purchasing an additional 34,652 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Genmab A/S Stock Up 3.3 %

Shares of GMAB traded up $0.77 during mid-day trading on Wednesday, hitting $24.10. The stock had a trading volume of 604,007 shares, compared to its average volume of 857,756. The company has a market cap of $15.95 billion, a PE ratio of 13.85, a PEG ratio of 2.65 and a beta of 0.96. The company's fifty day simple moving average is $21.16 and its two-hundred day simple moving average is $22.71. Genmab A/S has a fifty-two week low of $18.64 and a fifty-two week high of $31.88.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Equities analysts expect that Genmab A/S will post 1.45 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on GMAB. Sanford C. Bernstein raised shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Friday, December 20th. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective on the stock in a report on Thursday, February 13th. BMO Capital Markets reissued an "outperform" rating and set a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Finally, BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Four investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $42.17.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.